PANTHER (version 1, 16 November 2009)

• Research type

  Research Study

• Full title

  A Phase II Study Investigating Upfront Pazopanib in Metastatic Clear Cell Renal Cancer [PANTHER]

• IRAS ID

  33688

• Contact name

  Thomas Powles

• Sponsor organisation

  East London NHS Foundation Trust

• Eudract number

  2009-016675-29

• ISRCTN Number

  N/A

• Research summary

  When kidney cancer spreads beyond the kidney, it is known as metastatic kidney cancer. This is very difficult to treat and almost all the patients will die of their disease within 3 years. Historically patients were treated with surgical removal of the kidney (nephrectomy) followed by immune therapy (interferon), which treatment of disease by inducing, enhancing or suppressing an immune response. However the standard treatment for this type of cancer has recently changed. A new class of oral drugs called the tyrosine kinase inhibitors have taken over the previous treatments. Sunitinib is one of drugs and is standard therapy in kidney cancer in the UK. Pazopanib is also a tyrosine kinase inhibitor with good activity in renal cancer. Initial results in patients suggest it will be as good as sunitinib in renal cancer but may be better tolerated. The role of the surgical removal of the kidney has now become unclear. To date there have been clinical studies looking at giving a period of initial sunitinib followed by surgery. These studies are designed to obtain control of the disease before the surgery takes place making the surgery easier and treating the metastatic sites more quickly. The principal of the study proposed here is to give an initial period of pazopanib prior to surgery. We expect the drug to shrink down the cancer prior to the surgery and get control of the disease that has spread beyond the kidney making the surgery easier.

• REC name

  London - South East Research Ethics Committee

• REC reference

  09/H1102/115

• Date of REC Opinion

  22 Feb 2010

• REC opinion

  Further Information Favourable Opinion